Overview

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Timolol
Criteria
Inclusion Criteria:

- Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on
beta-blocker monotherapy or dual therapy in which at least one medication is a
beta-blocker for at least 4 weeks prior to screening

Exclusion Criteria:

- Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.

- History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months
prior to screening